TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Aditya Bardia; Komal Jhaveri; Kevin Kalinsky; Sonia Pernas; Junji Tsurutani; Binghe Xu; Erika Hamilton; Seock Ah Im; Zbigniew Nowecki; Joohyuk Sohn; Michelino De Laurentiis; Noelia Martínez Jañez; Barbara Adamo; Keun Seok Lee; Kyung Hae Jung; Gábor Rubovszky; Ling Ming Tseng; Yen Shen Lu; Yuan Yuan; Micah J. Maxwell; Vincent Haddad; Sabrina S. Khan; Hope S. Rugo; Barbara Pistilli

doi:10.2217/fon-2023-0188

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Pernas, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laurentiis, Noelia Martínez Jañez, Barbara Adamo, Keun Seok Lee, Kyung Hae Jung, Gábor Rubovszky, Ling Ming Tseng, Yen Shen Lu, Yuan Yuan, Micah J. MaxwellVincent Haddad, Sabrina S. Khan, Hope S. Rugo, Barbara Pistilli

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

16 Citations (Scopus)

Résumé

Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).

langue originale	Anglais
Pages (de - à)	423-436
Nombre de pages	14
journal	Future Oncology
Volume	20
Numéro de publication	8
Les DOIs	https://doi.org/10.2217/fon-2023-0188
état	Publié - 1 janv. 2023

Accès au document

10.2217/fon-2023-0188

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S. A., Nowecki, Z., Sohn, J., De Laurentiis, M., Jañez, N. M., Adamo, B., Lee, K. S., Jung, K. H., Rubovszky, G., Tseng, L. M., Lu, Y. S., Yuan, Y., ... Pistilli, B. (2023). TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncology, 20(8), 423-436. https://doi.org/10.2217/fon-2023-0188

@article{1c6b75194bbe4e0bbf849f9b1e0eefe0,

title = "TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer",

abstract = "Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).",

keywords = "ADC, Dato-DXd, HR-positive/HER2-negative, TROP2, Trophoblast cell surface antigen 2, antibody-drug conjugate, datopotamab deruxtecan, inoperable breast cancer, metastatic breast cancer",

author = "Aditya Bardia and Komal Jhaveri and Kevin Kalinsky and Sonia Pernas and Junji Tsurutani and Binghe Xu and Erika Hamilton and Im, {Seock Ah} and Zbigniew Nowecki and Joohyuk Sohn and {De Laurentiis}, Michelino and Ja{\~n}ez, {Noelia Mart{\'i}nez} and Barbara Adamo and Lee, {Keun Seok} and Jung, {Kyung Hae} and G{\'a}bor Rubovszky and Tseng, {Ling Ming} and Lu, {Yen Shen} and Yuan Yuan and Maxwell, {Micah J.} and Vincent Haddad and Khan, {Sabrina S.} and Rugo, {Hope S.} and Barbara Pistilli",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

month = jan,

day = "1",

doi = "10.2217/fon-2023-0188",

language = "English",

volume = "20",

pages = "423--436",

journal = "Future Oncology",

issn = "1479-6694",

number = "8",

}

Bardia, A, Jhaveri, K, Kalinsky, K, Pernas, S, Tsurutani, J, Xu, B, Hamilton, E, Im, SA, Nowecki, Z, Sohn, J, De Laurentiis, M, Jañez, NM, Adamo, B, Lee, KS, Jung, KH, Rubovszky, G, Tseng, LM, Lu, YS, Yuan, Y, Maxwell, MJ, Haddad, V, Khan, SS, Rugo, HS & Pistilli, B 2023, 'TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer', Future Oncology, VOL. 20, Numéro 8, p. 423-436. https://doi.org/10.2217/fon-2023-0188

TY - JOUR

T1 - TROPION-Breast01

T2 - Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

AU - Bardia, Aditya

AU - Jhaveri, Komal

AU - Kalinsky, Kevin

AU - Pernas, Sonia

AU - Tsurutani, Junji

AU - Xu, Binghe

AU - Hamilton, Erika

AU - Im, Seock Ah

AU - Nowecki, Zbigniew

AU - Sohn, Joohyuk

AU - De Laurentiis, Michelino

AU - Jañez, Noelia Martínez

AU - Adamo, Barbara

AU - Lee, Keun Seok

AU - Jung, Kyung Hae

AU - Rubovszky, Gábor

AU - Tseng, Ling Ming

AU - Lu, Yen Shen

AU - Yuan, Yuan

AU - Maxwell, Micah J.

AU - Haddad, Vincent

AU - Khan, Sabrina S.

AU - Rugo, Hope S.

AU - Pistilli, Barbara

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).

AB - Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).

KW - ADC

KW - Dato-DXd

KW - HR-positive/HER2-negative

KW - TROP2

KW - Trophoblast cell surface antigen 2

KW - antibody-drug conjugate

KW - datopotamab deruxtecan

KW - inoperable breast cancer

KW - metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85188200861&partnerID=8YFLogxK

U2 - 10.2217/fon-2023-0188

DO - 10.2217/fon-2023-0188

M3 - Review article

C2 - 37387213

AN - SCOPUS:85188200861

SN - 1479-6694

VL - 20

SP - 423

EP - 436

JO - Future Oncology

JF - Future Oncology

IS - 8

ER -